Pharmaceutical care on a patient with primary hyperparathyroidism
LI Xin
JI Li-wei
WANG Rui-tao
Abstract：One 79-year-old female patient with hypertension, type 2 diabetes, coronary heart disease and other diseases was hospitalized for primary hyperparathyroidism. After hospitalization, the patient received the reducing blood calcium, controlling blood pressure, hypoglycemic therapy and lipid-regulating therapy. Clinical pharmacists participated in the treatment, and monitored the potential adverse drug reactions of zoledronic acid injection. At the same time, according to the patient's condition, clinical pharmacists suggested optimizing the regimen of blood pressure controlling and hypoglycemic program. After 12 days, the disease made rapid progress and the patient was discharged.
Keywords：Primary hyperparathyroidismZoledronic acidAdverse drug reactionClinical pharmacistPharmaceutical care
Publication Date：2017-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：4( 30-33 )